APA (7th ed.) Citation

Masip, J. R., Besse, B., Aix, S. P., Callejo, A., Al-Rabi, K., Caro, R. B., . . . Dziadziuszko, R. (2022). LBA51 Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial. Annals of Oncology, 33, S1419. https://doi.org/10.1016/j.annonc.2022.08.053

Chicago Style (17th ed.) Citation

Masip, J. Remon, et al. "LBA51 Osimertinib Treatment Based on Plasma T790M Monitoring in Patients with EGFR-mutant Non-small Cell Lung Cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE Phase II Randomized Clinical Trial." Annals of Oncology 33 (2022): S1419. https://doi.org/10.1016/j.annonc.2022.08.053.

MLA (9th ed.) Citation

Masip, J. Remon, et al. "LBA51 Osimertinib Treatment Based on Plasma T790M Monitoring in Patients with EGFR-mutant Non-small Cell Lung Cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE Phase II Randomized Clinical Trial." Annals of Oncology, vol. 33, 2022, p. S1419, https://doi.org/10.1016/j.annonc.2022.08.053.